Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology

Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX) reported that IP Australia issued a Notice of Acceptance for a patent covering its breast cancer vaccine technology, exclusively licensed from Cleveland Clinic. Titled “Vaccine Adjuvants and Formulations,” the patent protects Anixa’s preventive and therapeutic breast cancer vaccine approach in Australia.

The patent complements existing coverage in the United States, Europe, China, Japan and other regions, expanding Anixa’s global intellectual property estate. A recently completed Phase 1 trial at Cleveland Clinic, funded by the U.S. Department of Defense, met major primary endpoints, showed safety and tolerability, and generated protocol-defined immune responses in over 74% of participants.

Positive

• Australian breast cancer vaccine patent accepted, expanding IP coverage to another key market
• Breast cancer vaccine Phase 1 trial met major primary endpoints and was safe and well tolerated
• Phase 1 study produced protocol-defined immune responses in over 74% of participants
• Patent complements issued rights in the US, Europe, China, Japan and other jurisdictions
• Exclusive license from Cleveland Clinic strengthens competitive position for vaccine platform

Negative

• Breast cancer vaccine has only completed a Phase 1 trial to date, with further development required

Market reaction after Australian patent acceptance for breast cancer vaccine: ANIX +4.25% in the Jul 14 session

+4.25%

20 alerts

+4.25% Session close to close

+13.7% Peak in 27 hr 21 min

$104.11M Market Cap

1.2x Rel. Volume

In the Jul 14 session, ANIX gained 4.25%, reflecting a moderate positive market reaction. Argus tracked a peak move of +13.7% during that session. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

With low reported short positioning and recent insider net buying totaling 28,836 shares, this Austr...

Analysis

With low reported short positioning and recent insider net buying totaling 28,836 shares, this Australian patent notice slots into a backdrop of supportive ownership signals. Investors may still weigh it against the unused $100,000,000 S‑3 shelf capacity and ongoing funding needs.

Key Figures

Immune response rate: more than 74% of participants

1 metrics

Immune response rate more than 74% of participants Completed Phase 1 breast cancer vaccine trial

Historical Context

5 past events · Latest: Jul 06 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 06	Ovarian CAR-T dose escalation	Positive	-6.7%	Advanced ovarian cancer CAR-T Phase 1 to higher dose with no dose-limiting toxicities.
Jun 29	Korean breast vaccine patent	Positive	+2.1%	Secured first Korean patent for breast cancer vaccine with protection through 2040.
Jun 26	Breast vaccine and CAR-T data	Positive	+6.5%	Reported positive Phase 1 breast vaccine data and encouraging CAR-T survival outcomes.
Jun 11	Symposium presentation notice	Positive	+5.5%	Announced upcoming symposium presentations for breast cancer vaccine and ovarian CAR-T.
Jun 01	Canadian ovarian vaccine patent	Positive	+0.0%	Received Canadian Notice of Allowance for AMHR2-targeted ovarian cancer vaccine patent.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent Anixa news on patents and clinical progress has more often coincided with positive or flat next-day moves, though one key clinical update drew a negative reaction.

Key Terms

vaccine adjuvants, cancer immunotherapy, triple-negative breast cancer, α-lactalbumin

4 terms

vaccine adjuvants medical

"The patent is titled, "Vaccine Adjuvants and Formulations,""

Vaccine adjuvants are substances added to a vaccine to strengthen and shape the body’s immune response, similar to how a small amplifier makes a speaker louder so a message carries farther. They matter to investors because adjuvants can improve a vaccine’s effectiveness, reduce the amount of active ingredient needed, affect production complexity and safety profiles, and therefore influence regulatory approval, manufacturing cost and market potential.

cancer immunotherapy medical

"reinforcing its leadership in the field of cancer immunotherapy."

Cancer immunotherapy is a group of treatments that help the body’s immune system recognize and attack cancer cells, like training the body’s soldiers to spot a hidden enemy. It matters to investors because these therapies can transform patient outcomes and create large markets if shown safe and effective, so clinical trial results, regulatory approvals, and manufacturing scale can drive significant changes in a company’s revenue and stock value.

triple-negative breast cancer medical

"particularly in aggressive forms of the disease such as triple-negative breast cancer."

Triple-negative breast cancer is a type of breast cancer that lacks three common markers used to identify and treat the disease effectively. Because it doesn’t respond to some targeted therapies, it can be more difficult to treat and may have a more aggressive progression. This impacts the development of new treatments and can influence the outlook for healthcare companies involved in cancer research and pharmaceuticals.

α-lactalbumin medical

"is based on immunizing against human α-lactalbumin, a protein associated with lactation"

α-lactalbumin is a naturally occurring protein found in mammalian milk that supplies essential building blocks and supports nutrient absorption; think of it as a concentrated, high-quality protein ingredient used to boost the nutritional value of infant formula, medical nutrition and some supplements. Investors care because its use, purity, and supply affect product claims, regulatory approvals, patent positions and consumer demand in nutrition and health markets—factors that influence revenue and margins.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Notice of Acceptance marks first Australian patent covering Anixa's breast cancer vaccine platform

Continues expansion of global intellectual property coverage in markets with increasing breast cancer incidence rates

SAN JOSE, Calif., July 14, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that IP Australia has issued a Notice of Acceptance for a new patent related to Anixa's breast cancer vaccine technology.

This patent, exclusively licensed from Cleveland Clinic, will provide protection for the Company's novel approach to breast cancer treatment and prevention in Australia. The patent is titled, "Vaccine Adjuvants and Formulations," and the co-inventors are Dr. Justin Johnson and the late Dr. Vincent Tuohy, both of Cleveland Clinic.

The acceptance further expands the international scope of Anixa's intellectual property portfolio, reinforcing its leadership in the field of cancer immunotherapy. The Australian patent complements patents issued in the United States and other key global jurisdictions, including Europe, China, and Japan, among others, and represents an important step toward potential future regulatory approvals and commercialization efforts outside the United States.

In a recently completed Phase 1 trial, at Cleveland Clinic and funded by the U.S. Department of Defense, the vaccine met all major primary endpoints, was safe and well tolerated, and generated protocol defined immune responses in more than 74% of participants. These results support continued clinical development of the Company's novel preventive and therapeutic breast cancer vaccine.

"This newly accepted patent continues the broad international recognition of the novelty and potential of our breast cancer vaccine," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "As we continue clinical development in the U.S., our growing international patent estate further strengthens our ability to pursue global opportunities and potentially partner with larger pharmaceutical companies for worldwide commercialization."

Breast cancer remains the most commonly diagnosed cancer among women worldwide, and while survival rates in Australia remain high, incidence rates have continued to increase. Despite significant advances in screening and treatment, there are currently no approved vaccines designed to prevent breast cancer.

Anixa's breast cancer vaccine is based on immunizing against human α-lactalbumin, a protein associated with lactation that is aberrantly expressed in certain types of breast cancer. This "retired" protein strategy, developed at Cleveland Clinic and licensed exclusively to Anixa, aims to selectively prime the immune system to prevent tumor formation while avoiding harm to normal tissue, particularly in aggressive forms of the disease such as triple-negative breast cancer.

By reinforcing its global patent estate, Anixa is laying the groundwork for future international development and commercialization strategies. The Company's broader vaccine platform also targets other high-incidence cancers and is designed to transform how the medical community approaches cancer prevention. If successful, the technology could represent one of the first preventive vaccine approaches targeting breast cancer.

About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.

Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-expands-global-patent-portfolio-with-australian-patent-acceptance-for-breast-cancer-vaccine-technology-302824585.html

SOURCE Anixa Biosciences, Inc.

FAQ

What did Anixa Biosciences (ANIX) announce about its breast cancer vaccine patent in Australia on July 14, 2026?

Anixa Biosciences announced that IP Australia issued a Notice of Acceptance for a patent covering its breast cancer vaccine platform. According to Anixa, this Australian patent protects its novel vaccine adjuvants and formulations and complements existing patents in the United States and other major markets.

How does the new Australian patent affect Anixa Biosciences’ (ANIX) global intellectual property strategy?

The Australian patent broadens Anixa’s international intellectual property coverage for its breast cancer vaccine technology. According to Anixa, it complements patents in the US, Europe, China, Japan and other jurisdictions, supporting potential future regulatory approvals and commercialization efforts outside the United States.

What were the key results of Anixa Biosciences’ Phase 1 breast cancer vaccine trial?

The Phase 1 trial met all major primary endpoints, was safe and well tolerated, and induced protocol-defined immune responses in over 74% of participants. According to Anixa, this Cleveland Clinic study, funded by the U.S. Department of Defense, supports continued clinical development of the vaccine.

What is the mechanism of Anixa Biosciences’ breast cancer vaccine targeting \\/-lactalbumin?

Anixa’s vaccine targets human α-lactalbumin, a lactation-associated protein aberrantly expressed in certain breast cancers. According to Anixa, this “retired” protein strategy aims to prime the immune system to prevent tumor formation while minimizing harm to normal tissues, including aggressive triple-negative breast cancer.

Does Anixa Biosciences’ breast cancer vaccine have regulatory approval or is it still in development?

Anixa’s breast cancer vaccine is still in clinical development and has completed a Phase 1 trial. According to Anixa, the newly accepted Australian patent and existing global IP rights lay groundwork for future regulatory pathways and possible commercialization, but no approvals are reported yet.

What types of cancers does Anixa Biosciences’ broader vaccine platform aim to address?

Anixa states its broader vaccine platform targets breast cancer and other high-incidence cancers. According to Anixa, the strategy is designed to change how medicine approaches cancer prevention, potentially enabling one of the first preventive vaccine approaches specifically targeting breast cancer if development is successful.